購物車 
冠狀病毒抑制劑|New coronavirus inhibitor
SARS-CoV（SARS冠狀病毒）是引起嚴(yán)重急性呼吸道綜合癥（SARS）的病毒。 冠狀病毒編碼的木瓜蛋白酶樣蛋白酶（PLpro）通常是具有蛋白酶活性的多功能酶，具有加工病毒復(fù)制酶多蛋白和去泛素化（DUB）/ deISGylating活性的作用，假定該酶可以修飾對感染的先天免疫應(yīng)答。冠狀病毒抑制劑主要用于新型新型冠狀病毒的先導(dǎo)化合物，進(jìn)行抗新型冠狀病毒（2019-nCoV）潛在藥物的篩選研究和新藥研發(fā)使用，不可直接應(yīng)用于人體使用。The study of the structure of virus is an important implication for the exploring and development of effective antivirals. At present, S protein, TMPRSS2, ACE2, RdRp, and Mpro are primary targets. For example, Lopinavir as a protease inhibitor combined with Ritonavir performs against antiretroviral activity. Remdesivir, as a nucleotide analogue, shows an effective activity against SARS-CoV-2 through inhibiting RdRp.
